Oncotelic Therapeutics (OTCQB: OTLC) and Sapu Nano announced that Chief Executive Officer Vuong Trieu will present the Deciparticle nanomedicine platform at the BIO International Convention 2026 in San Diego. The presentation will focus on the development of ultra-small nanomedicine formulations designed to enable intravenous administration of highly water-insoluble therapeutics. The Deciparticle platform utilizes proprietary amphiphilic polymer systems capable of forming sub-20 nanometer particles for oncology and other therapeutic applications.
The companies plan to showcase development progress across multiple Deciparticle programs, including Sapu006, a polysorbate-free intravenous docetaxel formulation moving into Phase 1b clinical evaluation, and Sapu003, an intravenous everolimus nanomedicine program currently in a global Phase 1b clinical trial. The presentation will also highlight the integration of artificial intelligence and knowledge-organization technologies into formulation development and translational oncology workflows through the PDAOAI platform.
This announcement is significant because it addresses a major challenge in drug development: many potent therapeutics are poorly water-soluble, limiting their clinical use. The Deciparticle platform's ability to form particles smaller than 20 nanometers could revolutionize the delivery of such drugs, potentially improving efficacy and reducing side effects. The use of AI in formulation development further accelerates the process, making it a key advancement in nanomedicine.
The presentation at BIO International Convention 2026, one of the largest biotechnology events globally, provides a platform for Oncotelic and Sapu Nano to engage with potential partners and investors. For more details, the full press release is available at https://ibn.fm/RUG7m.
Oncotelic Therapeutics is a clinical-stage biopharmaceutical company focused on oncology and immunotherapy products, with a mission to address high-unmet-need cancers and rare pediatric indications. The company leverages its proprietary AI-enabled PDAOAI platform to support research, biomarker discovery, and regulatory processes. Additionally, Oncotelic owns a 45% interest in GMP Bio, a joint venture advancing a complementary pipeline of therapeutic candidates. More information about Oncotelic can be found at https://ibn.fm/OTLC.
Sapu Nano is a biotechnology company developing next-generation nanomedicine platforms to improve drug delivery, enhance therapeutic index, and unlock new clinical potential for established and novel therapeutics, with a primary focus in oncology. The collaboration between Oncotelic and Sapu Nano represents a strategic effort to bring innovative nanomedicine solutions to the clinic.
